TickerGuard
Buy Day today: Neutral (59) Mixed market breadth · major macro event coming up
TAK

Takeda Pharmaceutical Co Ltd

Healthcare · Drug Manufacturers - Specialty & Generic

17.40$ -0.1% vs. previous close Closing price · As of: Aug 13, 2026

Statements

Cash Flow

Takeda Pharmaceutical Co Ltd (TAK) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2026), "Operating Cash Flow" came in at 1,041,431 million JPY. Tick rows to compare them in a chart.

All figures in millions of JPY.

Tick rows to compare them in a chart (up to 4)

Cash Flow TAK
Line item 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
182,517 25,491 261,363 377,854 328,479 669,752 1,010,931 1,123,105 977,156 716,344 1,057,182 1,041,431
260,951 197,381 171,426 182,127 247,691 583,649 559,671 583,151 664,400 728,002 761,396 721,127
20,350 14,714 15,385 18,610 20,084 29,122 37,663 43,374 60,672 70,871 72,867 72,775
-387 30,359 -67,011 -25,372 -49,042 -75,330 -200,526 169,881 21,003
262,326 -267,213 29,675 13,404 63,977 94,672 275,781 98,605 -25,264 -256,003 -59,372 199,905
108,718 84,857 112,027 128,262 134,114 217,710 236,468 186,037 633,689 480,730 379,625 414,659
91,347 -71,208 -655,691 -93,342 -2,835,698 292,119 393,530 -198,125 -607,102 -463,862 -367,060 -369,141
141,637 141,538 141,688 141,893 142,952 282,582 283,357 283,665 279,416 287,188 302,498 311,901
-17,587 -22,346 -23,117 -18,756 -1,172 -3,737 -2,141 -77,531 -26,929 -2,326 -51,860 -51,603
-995 45,917 471,421 -153,136 3,161,504 -586,090 -660,504 -600,477 -285,071 1,513 -314,314 1,076
-300,998 -124,839 289,896 -326,226 2,946,237 -1,005,213 -1,088,354 -1,070,265 -709,148 -354,416 -751,425 -496,820
-10,805 -203,817 -131,971 -46,730 407,120 -65,108 328,608 -116,527 -316,165 -75,730 -72,687 209,941
73,799 -59,366 149,336 249,592 194,365 452,042 774,463 937,068 343,467 235,614 677,557 626,772

Data as of: August 13, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?